PRME supply chain intelligence for Prime Medicine, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| AAV-REAGENT-PRODUCTION-CORE | AAV-REAGENT-PRODUCTION-CORE | 90% | We use our internal AAV Reagent Production Core, analytical development team, as well as outsourced resources and partners to generate AAV Prime Editors, quality control test as well as characterize them. |
| OUTSOURCED-RESOURCES-AND-PARTNERS | OUTSOURCED-RESOURCES-AND-PARTNERS | 90% | We use our internal AAV Reagent Production Core, analytical development team, as well as outsourced resources and partners to generate AAV Prime Editors, quality control test as well as characterize them. |
| BEAM-THERAPEUTICS-INC | BEAM-THERAPEUTICS-INC | 75% | The Company is currently engaged in arbitration proceedings with Beam Therapeutics, Inc., or Beam, regarding the parties’ collaboration and license agreement |
| CRBU | Caribou Biosciences, Inc. | 72% | tic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable, or unlikely to receive marketing approv… |
| CRBU | Caribou Biosciences, Inc. | 72% | Reciprocal relationship from CRBU graph: Reciprocal relationship from PRME graph: Reciprocal relationship from CRBU graph: Reciprocal relationship from PRME graph: tic effect in such experiments or s… |
| CRSP | CRISPR Therapeutics AG | 72% | Reciprocal relationship from CRSP graph: Reciprocal relationship from PRME graph: tic effect in such experiments or studies or they may have other characteristics that may make the product candidates… |
| CRSP | CRISPR Therapeutics AG | 72% | tic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable, or unlikely to receive marketing approv… |
| DTIL | Precision BioSciences, Inc. | 72% | tic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable, or unlikely to receive marketing approv… |
| DTIL | Precision BioSciences, Inc. | 72% | Reciprocal relationship from DTIL graph: Reciprocal relationship from PRME graph: Reciprocal relationship from DTIL graph: Reciprocal relationship from PRME graph: Reciprocal relationship from DTIL g… |
| EDIT | Editas Medicine, Inc. | 72% | Reciprocal relationship from EDIT graph: Reciprocal relationship from PRME graph: Reciprocal relationship from EDIT graph: Reciprocal relationship from PRME graph: Reciprocal relationship from EDIT g… |
| EDIT | Editas Medicine, Inc. | 72% | tic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable, or unlikely to receive marketing approv… |
| LLY | Eli Lilly and Company | 72% | tic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable, or unlikely to receive marketing approv… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from PRME graph: Reciprocal relationship from LLY graph: Reciprocal relationship from PRME graph: tic effect in such experiments or stu… |
| LXEO | Lexeo Therapeutics, Inc. | 72% | Reciprocal relationship from LXEO graph: Reciprocal relationship from PRME graph: Reciprocal relationship from LXEO graph: s, obtain marketing approval and ultimately commercialize them. If we are un… |
| MYGN | Myriad Genetics, Inc. | 72% | Reciprocal relationship from MYGN graph: Reciprocal relationship from PRME graph: ght. We also could be required to obtain a license from such third party to continue developing, manufacturing and ma… |
| MYGN | Myriad Genetics, Inc. | 72% | ght. We also could be required to obtain a license from such third party to continue developing, manufacturing and marketing product candidates we may develop and our technology. However, we may not … |
| NTLA | Intellia Therapeutics, Inc. | 72% | Reciprocal relationship from NTLA graph: Reciprocal relationship from PRME graph: tic effect in such experiments or studies or they may have other characteristics that may make the product candidates… |
| NTLA | Intellia Therapeutics, Inc. | 72% | tic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable, or unlikely to receive marketing approv… |
| SGMO | Sangamo Therapeutics, Inc. | 72% | tic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable, or unlikely to receive marketing approv… |
| SGMO | Sangamo Therapeutics, Inc. | 72% | Reciprocal relationship from SGMO graph: Reciprocal relationship from PRME graph: tic effect in such experiments or studies or they may have other characteristics that may make the product candidates… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from PRME graph: ght. We also could be required to obtain a license from such third party to continue developing, manufacturing and m… |
| SNYNF | Sanofi | 72% | ght. We also could be required to obtain a license from such third party to continue developing, manufacturing and marketing product candidates we may develop and our technology. However, we may not … |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BEAM | Beam Therapeutics Inc. | 72% | orm is expected to allow Prime Medicine to generate follow-on candidates rapidly and efficiently. In addition, we are identifying partnership opportunities to advance other programs. CGD, is our most… |
| BEAM | Beam Therapeutics Inc. | 72% | Reciprocal relationship from BEAM graph: Reciprocal relationship from PRME graph: orm is expected to allow Prime Medicine to generate follow-on candidates rapidly and efficiently. In addition, we are… |
| CRBU | Caribou Biosciences, Inc. | 72% | Reciprocal relationship from CRBU graph: Reciprocal relationship from PRME graph: tic effect in such experiments or studies or they may have other characteristics that may make the product candidates… |
| CRBU | Caribou Biosciences, Inc. | 72% | tic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable, or unlikely to receive marketing approv… |
| CRSP | CRISPR Therapeutics AG | 72% | tic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable, or unlikely to receive marketing approv… |
| CRSP | CRISPR Therapeutics AG | 72% | Reciprocal relationship from CRSP graph: Reciprocal relationship from PRME graph: tic effect in such experiments or studies or they may have other characteristics that may make the product candidates… |
| DTIL | Precision BioSciences, Inc. | 72% | tic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable, or unlikely to receive marketing approv… |
| DTIL | Precision BioSciences, Inc. | 72% | Reciprocal relationship from DTIL graph: Reciprocal relationship from PRME graph: tic effect in such experiments or studies or they may have other characteristics that may make the product candidates… |
| EDIT | Editas Medicine, Inc. | 72% | tic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable, or unlikely to receive marketing approv… |
| EDIT | Editas Medicine, Inc. | 72% | Reciprocal relationship from EDIT graph: Reciprocal relationship from PRME graph: tic effect in such experiments or studies or they may have other characteristics that may make the product candidates… |
| LLY | Eli Lilly and Company | 72% | tic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable, or unlikely to receive marketing approv… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from PRME graph: tic effect in such experiments or studies or they may have other characteristics that may make the product candidates … |
| LXEO | Lexeo Therapeutics, Inc. | 72% | Reciprocal relationship from LXEO graph: ply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reaso… |
| MYGN | Myriad Genetics, Inc. | 72% | ght. We also could be required to obtain a license from such third party to continue developing, manufacturing and marketing product candidates we may develop and our technology. However, we may not … |
| MYGN | Myriad Genetics, Inc. | 72% | Reciprocal relationship from MYGN graph: Reciprocal relationship from PRME graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from PRME graph: ght. We also could be required to o… |
| NTLA | Intellia Therapeutics, Inc. | 72% | tic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable, or unlikely to receive marketing approv… |
| NTLA | Intellia Therapeutics, Inc. | 72% | Reciprocal relationship from NTLA graph: Reciprocal relationship from PRME graph: tic effect in such experiments or studies or they may have other characteristics that may make the product candidates… |
| SGMO | Sangamo Therapeutics, Inc. | 72% | tic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable, or unlikely to receive marketing approv… |
| SGMO | Sangamo Therapeutics, Inc. | 72% | Reciprocal relationship from SGMO graph: Reciprocal relationship from PRME graph: Reciprocal relationship from SGMO graph: Reciprocal relationship from PRME graph: Reciprocal relationship from SGMO g… |
| SNYNF | Sanofi | 72% | ght. We also could be required to obtain a license from such third party to continue developing, manufacturing and marketing product candidates we may develop and our technology. However, we may not … |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from PRME graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from PRME graph: Reciprocal relationship from SNYN… |
| K-EMERGING-GROWTH-COMPANY | K-EMERGING-GROWTH-COMPANY | 62% | ed as prepaid expenses and other current assets. If the expenses incurred exceed payments made, the difference is reflected as accrued expenses and other current liabilities. Non-refundable advance p… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| PRME-DEBT-11894 | Warrants outstanding: 18800000 | 90% | xbrl warrant detail from xbrl 2024-12-31. |
| PRME-DEBT | Debt stack $114.5M | 90% | Market cache reports total debt of $114.5M. |
| PRME-DEBT-11895 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2022-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| PRME-OWNER-ALPHABET-INC | Alphabet Inc. | 90% | 13F overlay lists Alphabet Inc. as top holder; 194 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| CRSP | CRISPR Therapeutics AG | 100.00 | 1 | ['customer', 'supplier'] |
| IBIO | iBio, Inc. | 100.00 | 2 | |
| SDGR | Schrödinger, Inc. | 100.00 | 2 | |
| CPMV | Mosaic ImmunoEngineering, Inc. | 100.00 | 2 | |
| BMY | Bristol-Myers Squibb Company | 100.00 | 1 | ['receiving'] |
| HOWL | Werewolf Therapeutics, Inc. | 100.00 | 2 | |
| CHRS | Coherus Oncology, Inc. | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 100.00 | 2 | ['customer', 'supplier'] |
| TLSA | Tiziana Life Sciences Ltd | 100.00 | 2 | |
| EMMA | Emmaus Life Sciences, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| CLLS | Cellectis S.A. | 100.00 | 2 | |
| BMYMP | Bristol-Myers Squibb Co | 100.00 | 1 | ['receiving'] |
| DRTS | Alpha Tau Medical Ltd. | 100.00 | 2 | |
| BEAM | Beam Therapeutics Inc. | 100.00 | 1 | ['customer'] |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| CRBU | Caribou Biosciences, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| DTIL | Precision BioSciences, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| WHWK | Whitehawk Therapeutics, Inc. | 100.00 | 2 | |
| JANX | Janux Therapeutics, Inc. | 100.00 | 2 |